First-line treatment for CLL in the era of targeted therapy
Abstract In the decade since FDA approval of the first-generation Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib, the treatment landscape for chronic lymphocytic leukemia (CLL) has transformed. Targeted agents, as monotherapy or in combination regimens, have decisively replaced chemoimmunotherap...
Spremljeno u:
| Glavni autori: | , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Nature Publishing Group
2026-01-01
|
| Serija: | Blood Cancer Journal |
| Online pristup: | https://doi.org/10.1038/s41408-025-01434-2 |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|